

# A study of JNJ-77242113 in participants with moderate-to-severe plaque psoriasis

<b>Submission date</b> 03/02/2022	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 10/05/2022	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 04/10/2024	<b>Condition category</b> Skin and Connective Tissue Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Plaque psoriasis is a common, chronic, inflammatory condition, affecting about 3.5 million patients in the United States, European Union, and Japan. Despite several advanced treatment options, a large proportion of patients are not receiving these therapies and there is a need for safer options, fewer injections, and options for more effective oral medications. The investigational drug is called JNJ-77242113. It targets immune responses in the body and skin which impact diseases, such as psoriasis.

It is hoped that targeting this process may lead to less inflammation and a reduction in psoriasis disease activity. This study is designed to see if JNJ-77242113 is better than a placebo (dummy drug) in reducing psoriasis disease activity.

### Who can participate?

Patients aged 18 years and over with moderate to severe plaque psoriasis.

### What does the study involve?

This study will last for a maximum of 24 weeks and is divided into three parts:

1. Screening phase: 1 visit (up to 4 weeks)
2. Treatment phase: 7 visits (16 weeks)
3. Safety follow-up phase: 1 visit (4 weeks)

During study visits a variety of tests will be carried out including, but not limited to, blood pressure, heart activity, physical exam, questionnaires and blood samples. Patients will be randomly assigned to receive either oral JNJ-77242113 at one of five different dosing regimens or placebo twice a day during the treatment phase.

### What are the possible benefits and risks of participating?

There is no established benefit to participants of this study. Based on scientific theory, taking JNJ-77242113 may improve symptoms of plaque psoriasis. These benefits are not guaranteed to happen and there may not be any benefit to participants by being in this study. In addition, if participants are put into treatment Group 6 (placebo) they will not receive JNJ-77242113 and will only receive placebo during this study.

Participants may experience some benefit from participation in the study that is not due to receiving study drug, but due to regular visits and assessments monitoring overall health.

Participation may help other people with psoriasis in the future. Not all possible side effects and risks related to JNJ-77242113 are known and it is possible that unexpected side effects may arise or may be life-threatening. To minimise the risk associated with this, participants are frequently reviewed at every visit for side effects and adverse events. Participants are educated to report any such problems to the study staff without delay. Any serious adverse events that are reported to the sponsor are thoroughly reviewed by a specialist drug safety team and the sponsor has implemented an Independent Data Review Committee. The participant information sheet, which will be signed by every participant agreeing to participate in the study, includes a detailed section outlining all known risks/side effects to participating in the study.

Where is the study run from?

Janssen-Cilag International NV is the sponsor for this study. The study will be run at multiple healthcare locations both within the UK and around the world.

When is the study starting and how long is it expected to run for?

January 2022 to February 2023

Who is funding the study?

Janssen Research & Development, LLC (Belgium)

Who is the main contact?

Sarah Currie (JanssenUKRegistryQueries@its.jnj.com)

## Contact information

### Type(s)

Principal investigator

### Contact name

Dr Andrew Pink

### ORCID ID

<https://orcid.org/0000-0001-5151-5539>

### Contact details

Guy's Hospital  
Great Maze Pond  
London  
United Kingdom  
SE1 9RT

### Type(s)

Scientific

### Contact name

Dr Medical Information and Product Information Enquiry

### Contact details

50-100 Holmers Farm Way  
High Wycombe

United Kingdom  
HP12 4DP  
+44 (0)800 731 8450 / 10494 567 444  
medinfo@its.jnj.com

## **Additional identifiers**

**Clinical Trials Information System (CTIS)**  
2021-003700-41

**Integrated Research Application System (IRAS)**  
1004415

**ClinicalTrials.gov (NCT)**  
NCT05223868

**Protocol serial number**  
77242113PSO2001, IRAS 1004415, CPMS 51021

## **Study information**

### **Scientific Title**

A Phase IIb multicenter, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis

### **Acronym**

FRONTIER 1

### **Study objectives**

Main objectives:

1. To evaluate the dose-response of JNJ-77242113 at Week 16 in participants with moderate-to-severe plaque psoriasis

Secondary objectives:

2. To characterize the additional efficacy of JNJ-77242113 versus placebo in participants with moderate-to-severe plaque psoriasis
3. To evaluate the effect of JNJ-77242113 treatment on patient-reported psoriasis severity versus placebo in participants with moderate-to-severe plaque psoriasis
4. To evaluate the effect of JNJ-77242113 treatment on dermatology-specific health-related quality of life versus placebo in participants with moderate-to-severe plaque psoriasis
5. To evaluate the effect of JNJ-77242113 treatment on general health-related quality of life versus placebo in participants with moderate-to-severe plaque psoriasis
6. To assess the safety and tolerability of JNJ-77242113 in participants with moderate-to-severe plaque psoriasis

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Approved 11/04/2022, London-Westminster Research Ethics Committee (Equinox House, City Link, Nottingham, NG2 4LA, UK; +44 (0)207 104 8066, +44 (0)207 1048236; westminster.rec@hra.nhs.uk), ref: 22/LO/0125

## **Study design**

Multicentre double-blind parallel-group randomized placebo-controlled trial

## **Primary study design**

Interventional

## **Study type(s)**

Treatment

## **Health condition(s) or problem(s) studied**

Plaque psoriasis

## **Interventions**

The total duration of this study is up to 24 weeks which includes a screening period of less than or equal to ( $\leq$ ) 4 weeks, a 16-week treatment period, and a 4-week safety follow-up period. Participants will be randomly assigned to one of 6 treatment arms by an online interactive web randomisation system tool. Each active cohort group will also receive a placebo to maintain blinding of dose regimens throughout the trial:

Group 1 will receive dose 1 of JNJ-77242113 once daily and placebo  
Group 2 will receive dose 2 of JNJ-77242113 once daily and placebo  
Group 3 will receive dose 3 of JNJ-77242113 once daily and placebo  
Group 4 will receive dose 1 of JNJ-77242113 twice daily and placebo  
Group 5 will receive dose 3 of JNJ-77242113 twice daily and placebo  
Group 6 will receive placebo twice daily

## **Intervention Type**

Drug

## **Phase**

Phase II

## **Drug/device/biological/vaccine name(s)**

JNJ-77242113

## **Primary outcome(s)**

Percentage of participants achieving Psoriasis Area Severity Index (PASI) 75 score (greater than or equal to  $\geq$  75 percentage [%] improvement from baseline in PASI) determined at Week 16. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.

## **Key secondary outcome(s)**

1. Change from baseline in PASI Total Score reported at Week 16. Change from baseline in PASI total score will be minored from baseline to week 16 and reported at Week 16
2. Percentage of participants achieving PASI 90 score ( $\geq 90\%$  improvement from baseline in PASI) determined at Week 16
3. Percentage of participants achieving PASI 100 score (100% improvement from baseline in PASI) determined at Week 16
4. Percentage of participants achieving an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) determined at Week 16. The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4)
5. Percentage of participants achieving an Investigator's Global Assessment (IGA) Score of Cleared (0) determined at Week 16
6. Change from baseline in Body Surface Area (BSA) reported at Week 16. Body Surface Area is a commonly used measure of severity of skin disease. It is defined as the percentage of the surface area of the body involved with the condition being assessed, (that is, plaque psoriasis)
7. Change from baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptoms Scores reported at Week 16. The PSSD includes a patient-reported outcome (PRO) questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two subscores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
8. Change from baseline in PSSD Signs Score reported at Week 16
9. Percentage of participants achieving PSSD Symptoms Score = 0 determined at Week 16 in participants with a baseline Symptoms Score  $\geq 1$
10. Percentage of participants achieving PSSD Sign Score = 0 determined at Week 16 in participants with a baseline Sign Score  $\geq 1$
11. Percentage of participants achieving a Dermatology Life Quality Index (DLQI) of 0 or 1 determined at Week 16 in participants with baseline DLQI Score  $> 1$ . The DLQI is a dermatology-specific health-related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past 7 days and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating a greater impact on HRQoL.
12. Change from baseline in Patient-reported Outcomes Measurement Information System (PROMIS-29) Domain Score reported at Week 16. The PROMIS-29 is a 29-item generic HRQoL instrument assessing 7 PROMIS domains (depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities) with 4 questions for each domain. These questions are ranked on a 5-point Likert scale. There is also a numerical rating scale that ranges from 0 (No pain) to 10 (Worst pain imaginable) for pain intensity. The raw domain scores are converted to standardized T-scores with a mean of 50 and a standard deviation of 10. Higher scores on anxiety, depression, fatigue, sleep disturbance, and pain interference indicate more severe symptoms. Higher scores on physical function and social participation indicate better health outcomes.
13. Percentage of participants achieving  $\geq 5$ -point improvement from baseline in PROMIS-29 Domain Score determined at Week 16
14. Number of participants with Adverse Events (AEs) monitored up to Week 24. An adverse event (AE) is any untoward medical event that occurs in a participant administered an

investigational product, and it does not necessarily indicate only events with a clear causal relationship with the relevant investigational product

15. Number of participants with Serious Adverse Events (SAEs) monitored up to Week 24. SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.

### **Completion date**

24/02/2023

## **Eligibility**

### **Key inclusion criteria**

1. Participant has a diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 6 months prior to the first administration of study intervention
2. Participant is a candidate for phototherapy or systemic treatment for plaque psoriasis
3. Participant has a total body surface area (BSA) greater than or equal to ( $\geq$ ) 10 percent (%) at screening and baseline
4. Participant has a total Psoriasis area and severity index (PASI)  $\geq 12$  at screening and baseline
5. Participant has a total Investigator global assessment (IGA)  $\geq 3$  at screening and baseline

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Adult

### **Sex**

All

### **Key exclusion criteria**

1. Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
2. Participant has current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta-blockers, calcium channel blockers, or lithium)
3. Participant have previously received any other therapeutic agent directly targeted to interleukin 23 receptor (IL-23R) (including but not limited to guselkumab, tildrakizumab, or risankizumab)
4. Participant has received any therapeutic agent directly targeted to interleukin 17 receptor (IL-17) or interleukin 12/23 receptor (IL-12/23) (including but not limited to secukinumab, ixekizumab, brodalumab, or ustekinumab) or has received anti-tumor necrosis factor [TNF]-alpha biologic therapy (including, but not limited to adalimumab) within 12 weeks or 5 half-lives, whichever is longer, of the first administration of study intervention
5. Participant has received agents that deplete B cells (including, but not limited to, rituximab, or alemtuzumab) within 26 weeks of the first administration of study intervention

**Date of first enrolment**

24/01/2022

**Date of final enrolment**

17/10/2022

**Locations****Countries of recruitment**

United Kingdom

England

Canada

Czech Republic

France

Germany

Japan

Korea, South

Poland

Spain

Taiwan

United States of America

**Study participating centre****Castle Hill Hospital**

Cottingham

United Kingdom

HU16 5JQ

**Study participating centre****Pinderfields Hospital**

Aberford Road

Wakefield

United Kingdom

WF1 4DG

**Study participating centre**  
**Russells Hall Hospital**  
Pensnett Road  
Dudley  
United Kingdom  
DY1 2HQ

**Study participating centre**  
**Guy's and St Thomas' Hospitals**  
Trust Offices  
Guy's Hospital  
Great Maze Pond  
London  
United Kingdom  
SE1 9RT

**Study participating centre**  
**Southampton General Hospital**  
Tremona Road  
Southampton  
United Kingdom  
SO16 6YD

**Study participating centre**  
**Innovaderm Research**  
3530 Boulevard Saint-Laurent  
Montreal  
Canada  
H2X 2V1

**Study participating centre**  
**Skin Centre For Dermatology**  
775 Monaghan Road  
Peterborough  
Canada  
K9J 5K2

**Study participating centre**  
**Dr. Chih-Ho Hong Medical**  
15300 105 Avenue  
Surrey

Canada  
V3R 6A7

**Study participating centre**  
**Dermedge Research**  
333 Lakeshore Road West  
Mississauga  
Canada  
L4Y 4C5

**Study participating centre**  
**K. Papp Clinical Research**  
135 Union Street East  
Waterloo  
Canada  
N2J 1C4

**Study participating centre**  
**Dermatology Research Institute Inc.**  
8500 Blackfoot Trail SE  
Calgary  
Canada  
T2J 7E1

**Study participating centre**  
**Xlr8 Medical Research**  
2425 Tecumseh Road East  
Windsor  
Canada  
N8W 1E6

**Study participating centre**  
**Dermatials Research**  
25 Charlton Avenue East  
Hamilton  
Canada  
L8N 1Y2

**Study participating centre**

**Fakultni Nemocnice Kralovske Vinohrady**

Srobarova 50

Praha

Czech Republic

775 20

**Study participating centre**

**Fn Plzen Dermatovenerologicka Klinika (Main)**

Edvarda Benese 13

Plzen

Czech Republic

305 99

**Study participating centre**

**Ccbr Klinicka Centra Czech, A.S.**

Trida Miru 2800

Pardubice

Czech Republic

53002

**Study participating centre**

**Nemocnice Ceske Budejovice, A.S.**

Bozeny Nemcove 54

Ceske Budejovice

Czech Republic

37087

**Study participating centre**

**Vseobecna Fakultní Nemocnice**

U Nemocnice 2

Praha 2

Czech Republic

128 08

**Study participating centre**

**Dermamedica S.R.O.**

Komenského 420

Nachod

Czech Republic

547 01

**Study participating centre**

**Clintrial S.R.O.**

Pocernicka 1427/16

Praha

Czech Republic

10 100 00

**Study participating centre**

**Nemocnice Na Bulovce**

Budinova 67/2

Praha 8

Czech Republic

180 81

**Study participating centre**

**Praglandia, S.R.O.**

Ostrovskeho 253/3

Prague

Czech Republic

15000

**Study participating centre**

**Dermatologie Prof. Hercogove**

Chlumcanskeho 497/5

Prague

Czech Republic

180 81

**Study participating centre**

**Ccr Prague S.R.O.**

Vinohradska 1597/174

Praha

Czech Republic

130 00

**Study participating centre**

**Hia Sainte Anne**

2 boulevard Sainte Anne

Toulon

France  
83800

**Study participating centre**  
**Hopital Charles Nicolle**  
1 rue de Germont  
Rouen  
France  
76031

**Study participating centre**  
**Hôpital Edouard Herriot**  
5 Pl D Arsonval  
Lyon Cedex 03  
France  
69437

**Study participating centre**  
**Centre Hospitalier Le Mans**  
194 Avenue Rubillard  
Le Mans  
France  
72037

**Study participating centre**  
**Chu Saint-Etienne**  
Avenue Albert Raimond  
St Priest En Jarez  
France  
42270

**Study participating centre**  
**Polyclinique De Courlancy**  
38bis Rue de Courlancy  
Reims  
France  
51100

**Study participating centre**

**Chu De Grenoble - Hôpital Albert Michallon**  
Boulevard de la Chantourne  
La Tronche  
France  
38700

**Study participating centre**  
**Ich Hopital A. Morvan**  
2 Avenue Marechal Foch  
Brest  
France  
29200

**Study participating centre**  
**Universitätsklinikum Carl Gustav Carus Dresden**  
Fetscherstr. 74  
Dresden  
Germany  
01307

**Study participating centre**  
**Mensingderma Research GmbH**  
Heegbarg 4  
Hamburg  
Germany  
22391

**Study participating centre**  
**Universitätsklinikum Schleswig-Holstein - Kiel**  
Arnold-Heller-Str. 3, Haus 19  
Kiel  
Germany  
24105

**Study participating centre**  
**Praxis Für Dermatologie Und Venerologie**  
Hauptstrasse 36a  
Dresden  
Germany  
01097

**Study participating centre**  
**Rothhaar Studien Gmbh**  
Dermatologisches Studienzentrum  
Berlin  
Germany  
10783

**Study participating centre**  
**Hautarztpraxis**  
Annenstraße 151  
Witten  
Germany  
58453

**Study participating centre**  
**Charite - Universitätsmedizin Berlin (Ccm)**  
Charitéplatz 1  
Berlin  
Germany  
10117

**Study participating centre**  
**Uniklinik Münster -Klinik U. Pol. F. Hautkrankheiten**  
Von-Esmarch-Straße 58  
Munster  
Germany  
48149

**Study participating centre**  
**Niesmann & Othlinghaus Gbr**  
Alleestraße 80  
Bochum  
Germany  
44793

**Study participating centre**  
**Universitätsklinikum Frankfurt**  
Theodor-Stern-Kai 7  
Frankfurt am Main

Germany  
60590

**Study participating centre**  
**Universitätsklinikum Heidelberg**  
Im Neuenheimer Feld 440  
Heidelberg  
Germany  
69120

**Study participating centre**  
**Dermatologische Gemeinschaftspraxis**  
Am Bahnhof 1  
Mahlow  
Germany  
15831

**Study participating centre**  
**Universitätsklinikum Leipzig AöR**  
Klinik f. Dermatologie  
Leipzig  
Germany  
04103

**Study participating centre**  
**Isa - Interdisciplinary Study Association Gmbh**  
Rankestrasse 34  
Berlin  
Germany  
10789

**Study participating centre**  
**Universitätsmedizin Der Johannes Gutenberg-Universität Mainz**  
Langenbeckstrasse 1  
Mainz  
Germany  
55131

**Study participating centre**

**Fachklinik Bad Bentheim**

Am Bade 1  
Bad Bentheim  
Germany  
48455

**Study participating centre**

**Rosenpark Research GmbH**

Rheinstrasse 1  
Darmstadt  
Germany  
64283

**Study participating centre**

**Universitätsklinikum Bonn**

Klinik und Poliklinik für Dermatologie und Allergologie  
Bonn  
Germany  
53127

**Study participating centre**

**Universitätsklinikum Koeln**

Kerpener Str. 62  
Koeln  
Germany  
50937

**Study participating centre**

**Derma-Study-Center Friedrichshafen GmbH**

Charlottenstrasse 12/1  
Friedrichshafen  
Germany  
88045

**Study participating centre**

**Seibo International Catholic Hospital**

2-5-1 Nakaochiai, Shinjuku-ku  
Tokyo  
Japan  
161-8521

**Study participating centre**

**Kume Clinic**

1-65-2, Otorihigashimachi, Nishi Ku  
Osaka Fu  
Japan  
593-8324

**Study participating centre**

**Miyata Dermatology Clinic**

1147 Matsudo  
Matsudo  
Japan  
271-0092

**Study participating centre**

**Sapporo Skin Clinic**

2-1-1 Minami-3Jo Nishi  
Sapporo  
Japan  
060-0063

**Study participating centre**

**Takagi Clinic**

Nishi-sanjo Minami 4-16  
Obihiro-shi  
Japan  
080-0013

**Study participating centre**

**Yamanashi Prefectural Central Hospital**

1-1-1 Fujimi, Kofu-City, Yamanashi  
Kofu  
Japan  
400-8506

**Study participating centre**

**Nomura Dermatology Clinic**

4-27-14 tanmachi  
Yokohama

Japan  
221-0825

**Study participating centre**

**Meiwa Hospital**  
4-31, Agenaruo cho  
Nishinomiya  
Japan  
663-8186

**Study participating centre**

**Charme Clinique**  
68-5, Akiyama  
Matsudo-shi  
Japan  
270-2223

**Study participating centre**

**Shizuoka Prefectural General Hospital**  
4-27-1, Kitaando, Aoi-ku  
Shizuoka  
Japan  
420-8527

**Study participating centre**

**Kumamoto Kenhoku Hospital**  
550, Tamana  
Tamana  
Japan  
865-0005

**Study participating centre**

**Shirasaki Dermatology Clinic**  
3-5-33 Ekinan  
Takaoka  
Japan  
933-0871

**Study participating centre**

**Toyama Prefectural Central Hospital**  
2-2-78 Nishinagae Toyama-shi  
Toyama  
Japan  
930-8550

**Study participating centre**  
**Mita Dermatology Clinic**  
4-5-8,Shiba  
Minato  
Japan  
108-0014

**Study participating centre**  
**Seoul National University Bundang Hospital**  
82, Gumi-ro,173 Beon-gil  
Seongnam  
Korea, South  
463-707

**Study participating centre**  
**Konkuk University Medical Center**  
120-1 NeunGdong-ro, Gwangjin-Gu  
Seoul  
Korea, South  
05030

**Study participating centre**  
**Pusan National University Hospital**  
179 Gudeok-Ro  
Busan  
Korea, South  
49241

**Study participating centre**  
**Kyunghee University Hospital**  
23 Kyungheedaero  
Seoul  
Korea, South  
102-1703

**Study participating centre**  
**Asan Medical Center**  
88, Olympic-ro 43-gil, Songpa-gu,  
Seoul  
Korea, South  
05505

**Study participating centre**  
**Seoul National University Hospital**  
101, Daehak-ro  
Seoul  
Korea, South  
03080

**Study participating centre**  
**Severance Hospital, Yonsei University Health System**  
50-1, Yonsei-ro, Seodaemun-gu  
Seoul  
Korea, South  
03722

**Study participating centre**  
**Wromedica**  
Mickiewicza 91  
Wroclaw  
Poland  
51-685

**Study participating centre**  
**Dermodent Centrum Medyczne Aldona Czajkowska Rafał Czajkowski S.C.**  
Tuberozy 3  
Osielsko  
Poland  
86031

**Study participating centre**  
**Nzoz Zdrowie Osteo-Medic**  
ul. Wiejska 81,  
Białystok

Poland  
15-351

**Study participating centre**  
**Dermed Centrum Medyczne Sp. Z O.O**  
ul. Piotrkowska 48  
Lodz  
Poland  
90-265

**Study participating centre**  
**Royalderm Agnieszka Nawrocka**  
K.Kieślowskiego 3B/3  
Warszawa  
Poland  
02962

**Study participating centre**  
**Klinika Ambroziak Estederm Sp. Z O.O**  
Kosiarzy 9A  
Warsaw  
Poland  
02-953

**Study participating centre**  
**Nzoz Specderm**  
Kardynała Stefana Wyszyńskiego 10 lokal 11  
Białystok  
Poland  
15-888

**Study participating centre**  
**Diamond Clinic Specjalistyczne Poradnie Lekarskie**  
Stefana Rogozińskiego 6/U3  
Krakow  
Poland  
31-559

**Study participating centre**

**Hosp. Univ. I Politecni La Fe**

Avda. Fernando Abril Martorell 106, Torre C, Planta 7  
Valencia  
Spain  
46026

**Study participating centre**

**Hosp. Univ. 12 De Octubre**

Avda. Cordoba sn  
Madrid  
Spain  
28041

**Study participating centre**

**Hosp. Univ. Germans Trias I Pujol**

Ctra. De Canyet s/n  
Barcelona  
Spain  
08916

**Study participating centre**

**Hosp. De Manises**

Av. De la Generalitat Valenciana 50  
Valencia  
Spain  
46940

**Study participating centre**

**Hosp. Provincial De Pontevedra**

C/ Simón Bolivar s/n  
Pontevedra  
Spain  
36001

**Study participating centre**

**Hosp. Univ. De Cruces**

Plaza de Cruces, S/N  
Barakaldo  
Spain  
48902

**Study participating centre**

**Hosp. Reina Sofia**

C/ Menéndez Pidal s/n

Córdoba

Spain

14004

**Study participating centre**

**Hosp. Univ. De Basurto**

Avenida de Montevideo, 18

Bilbao

Spain

48013

**Study participating centre**

**National Taiwan University Hospital**

Dermatology Department

Taipei City

Taiwan

10048

**Study participating centre**

**Chang-Gung Memorial Hospital, Linkou Branch**

No.5 Fuxing street

Taoyuan

Taiwan

333

**Study participating centre**

**National Cheng Kung University Hospital**

138 Sheng-Li Road

Tainan

Taiwan

70403

**Study participating centre**

**Chang Gung Memorial Hospital**

Kaohsiung Branch

Kaohsiung

Taiwan  
83342

**Study participating centre**  
**Windsor Dermatology, Pc**  
59 One Mile Rd Ext Ste G  
East Windsor  
United States of America  
08520

**Study participating centre**  
**Oregon Medical Research Center**  
9495 SW Locust Street  
Portland  
United States of America  
97223

**Study participating centre**  
**Arlington Dermatology**  
5301 Keystone Ct.  
Rolling Meadows  
United States of America  
60008

**Study participating centre**  
**Modern Research Associates**  
9101 N. Central Expressway  
Dallas  
United States of America  
75231

**Study participating centre**  
**Renstar Medical Research**  
21 NE 1st Ave  
Ocala  
United States of America  
34470

**Study participating centre**

**Dawes Fretzin Clinical Research Group, Llc**  
7910 N Shadeland Ave  
Indianapolis  
United States of America  
46250

**Study participating centre**  
**University Of Pittsburgh**  
Department Of Dermatology  
3601 5th Ave  
Pittsburgh  
United States of America  
15213

**Study participating centre**  
**Forcare Clinical Research, Inc.**  
15416 North Florida Avenue  
Tampa  
United States of America  
33613

**Study participating centre**  
**Clinical Partners**  
1524 Atwood Avenue  
Johnston  
United States of America  
02919

**Study participating centre**  
**Indiana Clinical Trial Center**  
824 Edwards Drive  
Plainfield  
United States of America  
46168

**Study participating centre**  
**Alliance Dermatology And Mohs Center, P.C.**  
4045 E Bell Rd  
Phoenix  
United States of America  
85032

**Study participating centre**  
**Austin Institute For Clinical Research**  
1601 E Pflugerville Pkwy  
Pflugerville  
United States of America  
78660

**Study participating centre**  
**Dermassociates, Pc**  
15245 Shady Grove Road  
Rockville  
United States of America  
20850

**Study participating centre**  
**Virginia Clinical Research**  
6160 Kempville Road  
Norfolk  
United States of America  
23502

**Study participating centre**  
**Oregon Dermatology And Research Center**  
2565 NW Lovejoy  
Portland  
United States of America  
97210

**Study participating centre**  
**Center For Clinical Studies**  
1401 Binz Street  
Houston  
United States of America  
77004

**Study participating centre**  
**University Of Utah**  
243 East 6100 South

Murray  
United States of America  
84107

**Study participating centre**  
**The South Bend Clinic Center For Research**  
211 N Eddy St  
South Bend  
United States of America  
46617-2808

**Study participating centre**  
**Alpha Dermatology Of Pa, Llc**  
670 Lawn Ave  
Sellersville  
United States of America  
18960

**Study participating centre**  
**Ccd Research, Plc**  
1 Willowbrook Road  
Cromwell  
United States of America  
06416

**Study participating centre**  
**Center For Clinical Studies**  
451 North Texas Avenue  
Webster  
United States of America  
77598

**Study participating centre**  
**Hamzavi Dermatology**  
2950 Keewahdin Road  
Fort Gratiot  
United States of America  
48059

**Study participating centre**  
**Vivida Dermatology**  
2110 East Flamingo Road, Suite 213  
Las Vegas  
United States of America  
89119

**Study participating centre**  
**Pacific Skin Institute**  
1495 River Park Drive  
Sacramento  
United States of America  
95815

**Study participating centre**  
**Synergy Clinical Research**  
595 Buckingham Way  
San Francisco  
United States of America  
94132

**Study participating centre**  
**Atlanta Dermatology, Vein & Research Center**  
11800 Atlantis Place  
Alpharetta  
United States of America  
30022

**Study participating centre**  
**Dermatology Associates**  
1730 Minor Avenue  
Seattle  
United States of America  
98101

**Study participating centre**  
**Medical Dermatology Specialists**  
1331 N. 7th Street  
Phoenix  
United States of America  
85006

**Study participating centre**  
**Premier Clinical Research**  
324 South Sherman  
Spokane  
United States of America  
99202

**Study participating centre**  
**Olympian Clinical Research**  
1201 S Myrtle Ave  
Clearwater  
United States of America  
33756

**Study participating centre**  
**Oakview Dermatology**  
2111 East State Street  
Athens  
United States of America  
45701

## **Sponsor information**

**Organisation**  
Janssen (Belgium)

**ROR**  
<https://ror.org/04yzcpd71>

## **Funder(s)**

**Funder type**  
Industry

**Funder Name**  
Janssen Research and Development

### Alternative Name(s)

Janssen R&D, Janssen Research & Development, Janssen Research & Development, LLC, Janssen Research & Development LLC, Janssen Pharmaceutical Companies of Johnson & Johnson, Research & Development at Janssen, JRD, J&J PRD

### Funding Body Type

Private sector organisation

### Funding Body Subtype

For-profit companies (industry)

### Location

United States of America

## Results and Publications

### Individual participant data (IPD) sharing plan

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at <https://www.janssen.com/clinicaltrials/transparency>. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at [yoda.yale.edu](http://yoda.yale.edu)

### IPD sharing plan summary

Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">HRA research summary</a>			28/06/2023	No	No
<a href="#">Other unpublished results</a>			04/10/2024	No	No